<p>Coppell Advisory Solutions LLC 在最近向证券交易委员会（SEC）提交的文件中表示，在第二季度将其在安进公司（NASDAQ:AMGN - 免费报告）的持股减少了 67.3%。该公司在季度内出售了 10,090 股后，持有 4,906 股该医疗研究公司的股票。Coppell Advisory Solutions LLC 在安进的持股在最近的报告期末价值为 1,360,000 美元。</p>
<ul>
<li>5 个医疗保健公司值得关注，因为行业轮动正在全面展开</li>
</ul>
<p>其他一些机构投资者最近也调整了对该公司的持股。B. Riley Wealth Advisors Inc. 在第二季度购买了安进的新股份，价值约为 1,647,000 美元。Newbridge Financial Services Group Inc. 在第二季度将其在安进的持股增加了 50.2%。Newbridge Financial Services Group Inc. 目前持有 640 股该医疗研究公司的股票，价值 179,000 美元，此前在上个季度增持了 214 股。Advisory Services Network LLC 在第二季度将其在安进的持股增加了 16.5%。Advisory Services Network LLC 目前持有 31,648 股该医疗研究公司的股票，价值 9,339,000 美元，此前在上个季度增持了 4,491 股。Anchor Investment Management LLC 在第二季度将其在安进的持股增加了 6.5%。Anchor Investment Management LLC 目前持有 4,942 股该医疗研究公司的股票，价值 1,380,000 美元，此前在上个季度增持了 301 股。最后，Asset Dedication LLC 在第二季度将其在安进的持股增加了 3.6%。Asset Dedication LLC 目前持有 11,617 股该医疗研究公司的股票，价值 3,244,000 美元，此前在上个季度增持了 409 股。76.50% 的股票目前由机构投资者持有。</p>
<h2>安进的内部买卖</h2>
<p>在相关消息中，SVP Rachna Khosla 于 11 月 12 日（星期三）出售了 890 股公司的股票。股票以平均价格 336.24 美元出售，总价值为 299,253.60 美元。交易完成后，这位高级副总裁持有 7,082 股公司股票，价值约为 2,381,251.68 美元。这代表其持股减少了 11.16%。该出售在向证券交易委员会的文件中披露，该文件可通过 SEC 网站访问。此外，EVP Murdo Gordon 于 11 月 12 日（星期三）出售了 6,879 股股票。股票以平均价格 336.83 美元出售，总交易额为 2,317,053.57 美元。交易完成后，这位执行副总裁直接持有 41,923 股公司股票，价值约为 14,120,924.09 美元。这代表其持股减少了 14.10%。该出售的 SEC 文件提供了更多信息。在过去的九十天里，内部人士共出售了 10,908 股公司股票，价值 3,674,966 美元。内部人士持有公司股票的比例为 0.76%。</p>
<h2>安进股票上涨 0.1%</h2>
<ul>
<li>安进股票：在盈利超预期后，新的历史高点即将到来</li>
</ul>
<p>安进股票在周五开盘价为 317.74 美元。该股票的 50 日简单移动平均线为 316.12 美元，200 日简单移动平均线为 298.78 美元。该股票的市值为 1711 亿美元，市盈率为 24.55，市盈增长比率为 2.87，贝塔系数为 0.45。该公司的债务与股本比率为 5.45，速动比率为 0.99，流动比率为 1.28。安进公司的 52 周低点为 253.30 美元，52 周高点为 346.38 美元。</p>
<p>安进（NASDAQ:AMGN - 获取免费报告）最近于 11 月 4 日（星期二）发布了季度财报。该医疗研究公司报告每股收益（EPS）为 5.64 美元，超出分析师一致预期的 5.01 美元，超出幅度为 0.63 美元。安进的股本回报率为 162.59%，净利润率为 19.47%。该公司在本季度的收入为 95.6 亿美元，而分析师预期为 89.8 亿美元。去年同期，该公司每股收益为 5.58 美元。该公司的收入同比增长 12.4%。安进已将其 2025 财年的指引设定为每股收益 20.600-21.400 美元。分析师预计安进公司今年的每股收益为 20.62 美元。</p>
<h2>安进增加股息</h2>
<ul>
<li>皇家制药如何在不承担生物技术最大风险的情况下创造现金</li>
</ul>
<p>该公司最近还披露了季度股息，将于 3 月 6 日（星期五）支付。2 月 13 日（星期五）的股东将获得每股 2.52 美元的股息。这相当于年化股息 10.08 美元，收益率为 3.2%。这比安进之前的季度股息 2.38 美元有所增加。该股息的除息日期为 2 月 13 日（星期五）。安进的股息支付比率（DPR）目前为 73.57%。</p>
<h2>分析师设定新的价格目标</h2>
<p>一些研究公司最近对 AMGN 进行了评估。Truist Financial 在 11 月 24 日（星期一）发布的研究报告中开始覆盖安进的股票。他们对该公司给予了 “持有” 评级，并设定了 318.00 美元的目标价格。汇丰银行在周三重申了 “买入” 评级，并设定了 425.00 美元的目标价格。Weiss Ratings 在 10 月 8 日（星期三）的研究报告中将安进的评级从 “持有（c+）” 上调至 “买入（b-）”。摩根士丹利在周五将安进的目标价格从 329.00 美元下调至 304.00 美元，并对该公司设定了 “同等权重” 评级。最后，Raymond James Financial 在 9 月 3 日（星期三）的研究报告中开始覆盖安进。他们对该股票设定了 “市场表现” 评级。一位分析师对该股票给予了强烈买入评级，十位分析师给予了买入评级，十位分析师给予了持有评级，一位分析师给予了卖出评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “适度买入”，共识目标价格为 332.85 美元。</p>
<p><strong>查看我们关于安进的最新研究报告</strong></p>
<h2>安进公司简介</h2>
<p>（免费报告）</p>
<p>安进公司在全球范围内发现、开发、生产和交付人类治疗药物。公司的主要产品包括用于治疗斑块型银屑病、类风湿性关节炎和银屑病关节炎的恩利昔（Enbrel）；用于治疗成人斑块型银屑病、银屑病关节炎和与贝赫切特病相关的口腔溃疡的 Otezla；用于治疗绝经后女性骨质疏松症的 Prolia；用于预防骨骼相关事件的 XGEVA；可降低心肌梗死、中风和冠状动脉再血管化风险的 Repatha；用于治疗免疫性血小板减少症患者的 Nplate；用于治疗复发性或难治性多发性骨髓瘤患者的 KYPROLIS；用于治疗红细胞数量低于正常水平和贫血的 Aranesp；用于治疗绝经后男性和女性骨质疏松症的 EVENITY；用于治疗野生型 RAS 转移性结直肠癌患者的 Vectibix；用于治疗急性淋巴细胞白血病患者的 BLINCYTO；用于治疗甲状腺眼病的 TEPEZZA；以及用于治疗慢性难治性痛风的 KRYSTEXXA。</p>
<h2>另请参见</h2>
<ul>
<li>我们更看好的五只股票超过安进</li>
<li>零售投资者如何交易多伦多证券交易所（TSX）？</li>
<li>迪士尼的 10 亿美元交易将其魔力带入 OpenAI</li>
<li>这些液化天然气股票是否准备迎来反弹？</li>
<li>为什么亚马逊可能在几周内成为 300 美元的股票</li>
<li>3 只杂货股票证明它们仍然是必需品</li>
<li>Adobe 在财报后获得提振：长期前景看涨</li>
</ul>
<p><strong>想知道其他对 AMGN 持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取安进公司（NASDAQ:AMGN - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在安进吗？</h2>
<p>在考虑安进之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而安进并不在名单上。</p>
<p>虽然安进目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

安进

<p>Coppell Advisory Solutions LLC 在第二季度减少了对安进（Amgen Inc.）的持股比例，降幅为 67.3%，目前持有价值 136 万美元的股份。其他机构投资者也调整了他们的持仓，其中一些增加了持股。内部交易方面，SVP Rachna Khosla 和 EVP Murdo Gordon 进行了股票出售。安进的股票表现略有上升，最近公布的财报超出预期，并宣布了分红。公司报告了强劲的财务数据，年同比收入增长 12.4%，并对盈利前景持积极态度</p>

<p>Coppell Advisory Solutions LLC decreased its position in Amgen Inc. (NASDAQ:AMGN - Free Report) by 67.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,906 shares of the medical research company's stock after selling 10,090 shares during the quarter. Coppell Advisory Solutions LLC's holdings in Amgen were worth $1,360,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>Coppell Advisory Solutions LLC 在最近向证券交易委员会（SEC）提交的文件中表示，在第二季度将其在安进公司（NASDAQ:AMGN - 免费报告）的持股减少了 67.3%。该公司在季度内出售了 10,090 股后，持有 4,906 股该医疗研究公司的股票。Coppell Advisory Solutions LLC 在安进的持股在最近的报告期末价值为 1,360,000 美元。</p>
</div><ul>
<li>5 Healthcare Names to Watch as Sector Rotation Is in Full Swing</li>
</ul>
<div class="lb-trans"><ul>
<li>5 个医疗保健公司值得关注，因为行业轮动正在全面展开</li>
</ul>
</div><p>A number of other institutional investors also recently modified their holdings of the company. B. Riley Wealth Advisors Inc. bought a new position in shares of Amgen during the second quarter worth about $1,647,000. Newbridge Financial Services Group Inc. boosted its position in Amgen by 50.2% during the 2nd quarter. Newbridge Financial Services Group Inc. now owns 640 shares of the medical research company's stock worth $179,000 after acquiring an additional 214 shares during the last quarter. Advisory Services Network LLC grew its stake in shares of Amgen by 16.5% during the 2nd quarter. Advisory Services Network LLC now owns 31,648 shares of the medical research company's stock worth $9,339,000 after acquiring an additional 4,491 shares in the last quarter. Anchor Investment Management LLC raised its holdings in shares of Amgen by 6.5% in the second quarter. Anchor Investment Management LLC now owns 4,942 shares of the medical research company's stock valued at $1,380,000 after purchasing an additional 301 shares during the last quarter. Finally, Asset Dedication LLC raised its holdings in shares of Amgen by 3.6% in the second quarter. Asset Dedication LLC now owns 11,617 shares of the medical research company's stock valued at $3,244,000 after purchasing an additional 409 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>其他一些机构投资者最近也调整了对该公司的持股。B. Riley Wealth Advisors Inc. 在第二季度购买了安进的新股份，价值约为 1,647,000 美元。Newbridge Financial Services Group Inc. 在第二季度将其在安进的持股增加了 50.2%。Newbridge Financial Services Group Inc. 目前持有 640 股该医疗研究公司的股票，价值 179,000 美元，此前在上个季度增持了 214 股。Advisory Services Network LLC 在第二季度将其在安进的持股增加了 16.5%。Advisory Services Network LLC 目前持有 31,648 股该医疗研究公司的股票，价值 9,339,000 美元，此前在上个季度增持了 4,491 股。Anchor Investment Management LLC 在第二季度将其在安进的持股增加了 6.5%。Anchor Investment Management LLC 目前持有 4,942 股该医疗研究公司的股票，价值 1,380,000 美元，此前在上个季度增持了 301 股。最后，Asset Dedication LLC 在第二季度将其在安进的持股增加了 3.6%。Asset Dedication LLC 目前持有 11,617 股该医疗研究公司的股票，价值 3,244,000 美元，此前在上个季度增持了 409 股。76.50% 的股票目前由机构投资者持有。</p>
</div><h2>Insider Buying and Selling at Amgen</h2>
<div class="lb-trans"><h2>安进的内部买卖</h2>
</div><p>In related news, SVP Rachna Khosla sold 890 shares of the company's stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $336.24, for a total value of $299,253.60. Following the transaction, the senior vice president owned 7,082 shares in the company, valued at approximately $2,381,251.68. This represents a 11.16% decrease in their position. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through the SEC website. Also, EVP Murdo Gordon sold 6,879 shares of the stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $336.83, for a total transaction of $2,317,053.57. Following the completion of the transaction, the executive vice president directly owned 41,923 shares in the company, valued at approximately $14,120,924.09. This represents a 14.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 10,908 shares of company stock worth $3,674,966 over the last ninety days. Insiders own 0.76% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，SVP Rachna Khosla 于 11 月 12 日（星期三）出售了 890 股公司的股票。股票以平均价格 336.24 美元出售，总价值为 299,253.60 美元。交易完成后，这位高级副总裁持有 7,082 股公司股票，价值约为 2,381,251.68 美元。这代表其持股减少了 11.16%。该出售在向证券交易委员会的文件中披露，该文件可通过 SEC 网站访问。此外，EVP Murdo Gordon 于 11 月 12 日（星期三）出售了 6,879 股股票。股票以平均价格 336.83 美元出售，总交易额为 2,317,053.57 美元。交易完成后，这位执行副总裁直接持有 41,923 股公司股票，价值约为 14,120,924.09 美元。这代表其持股减少了 14.10%。该出售的 SEC 文件提供了更多信息。在过去的九十天里，内部人士共出售了 10,908 股公司股票，价值 3,674,966 美元。内部人士持有公司股票的比例为 0.76%。</p>
</div><h2>Amgen Trading Up 0.1%</h2>
<div class="lb-trans"><h2>安进股票上涨 0.1%</h2>
</div><ul>
<li>Amgen Stock: New All-Time Highs Ahead After Earnings Beat</li>
</ul>
<div class="lb-trans"><ul>
<li>安进股票：在盈利超预期后，新的历史高点即将到来</li>
</ul>
</div><p>Amgen stock opened at $317.74 on Friday. The stock has a 50-day simple moving average of $316.12 and a 200 day simple moving average of $298.78. The stock has a market capitalization of $171.10 billion, a P/E ratio of 24.55, a PEG ratio of 2.87 and a beta of 0.45. The company has a debt-to-equity ratio of 5.45, a quick ratio of 0.99 and a current ratio of 1.28. Amgen Inc. has a 52 week low of $253.30 and a 52 week high of $346.38.</p>
<div class="lb-trans"><p>安进股票在周五开盘价为 317.74 美元。该股票的 50 日简单移动平均线为 316.12 美元，200 日简单移动平均线为 298.78 美元。该股票的市值为 1711 亿美元，市盈率为 24.55，市盈增长比率为 2.87，贝塔系数为 0.45。该公司的债务与股本比率为 5.45，速动比率为 0.99，流动比率为 1.28。安进公司的 52 周低点为 253.30 美元，52 周高点为 346.38 美元。</p>
</div><p>Amgen (NASDAQ:AMGN - Get Free Report) last released its quarterly earnings data on Tuesday, November 4th. The medical research company reported $5.64 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.01 by $0.63. Amgen had a return on equity of 162.59% and a net margin of 19.47%.The company had revenue of $9.56 billion during the quarter, compared to analysts' expectations of $8.98 billion. During the same period last year, the firm posted $5.58 earnings per share. The business's revenue was up 12.4% on a year-over-year basis. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. Analysts expect that Amgen Inc. will post 20.62 earnings per share for the current year.</p>
<div class="lb-trans"><p>安进（NASDAQ:AMGN - 获取免费报告）最近于 11 月 4 日（星期二）发布了季度财报。该医疗研究公司报告每股收益（EPS）为 5.64 美元，超出分析师一致预期的 5.01 美元，超出幅度为 0.63 美元。安进的股本回报率为 162.59%，净利润率为 19.47%。该公司在本季度的收入为 95.6 亿美元，而分析师预期为 89.8 亿美元。去年同期，该公司每股收益为 5.58 美元。该公司的收入同比增长 12.4%。安进已将其 2025 财年的指引设定为每股收益 20.600-21.400 美元。分析师预计安进公司今年的每股收益为 20.62 美元。</p>
</div><h2>Amgen Increases Dividend</h2>
<div class="lb-trans"><h2>安进增加股息</h2>
</div><ul>
<li>How Royalty Pharma Prints Cash Without Biotech's Biggest Risks</li>
</ul>
<div class="lb-trans"><ul>
<li>皇家制药如何在不承担生物技术最大风险的情况下创造现金</li>
</ul>
</div><p>The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, February 13th will be given a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a yield of 3.2%. This is a positive change from Amgen's previous quarterly dividend of $2.38. The ex-dividend date of this dividend is Friday, February 13th. Amgen's dividend payout ratio (DPR) is presently 73.57%.</p>
<div class="lb-trans"><p>该公司最近还披露了季度股息，将于 3 月 6 日（星期五）支付。2 月 13 日（星期五）的股东将获得每股 2.52 美元的股息。这相当于年化股息 10.08 美元，收益率为 3.2%。这比安进之前的季度股息 2.38 美元有所增加。该股息的除息日期为 2 月 13 日（星期五）。安进的股息支付比率（DPR）目前为 73.57%。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新的价格目标</h2>
</div><p>A number of research firms recently weighed in on AMGN. Truist Financial started coverage on shares of Amgen in a research report on Monday, November 24th. They issued a &#34;hold&#34; rating and a $318.00 target price for the company. HSBC restated a &#34;buy&#34; rating and set a $425.00 price objective on shares of Amgen in a research note on Wednesday. Weiss Ratings raised Amgen from a &#34;hold (c+)&#34; rating to a &#34;buy (b-)&#34; rating in a research report on Wednesday, October 8th. Morgan Stanley reduced their price target on Amgen from $329.00 to $304.00 and set an &#34;equal weight&#34; rating for the company in a research report on Friday. Finally, Raymond James Financial began coverage on Amgen in a research report on Wednesday, September 3rd. They set a &#34;market perform&#34; rating on the stock. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $332.85.</p>
<div class="lb-trans"><p>一些研究公司最近对 AMGN 进行了评估。Truist Financial 在 11 月 24 日（星期一）发布的研究报告中开始覆盖安进的股票。他们对该公司给予了 “持有” 评级，并设定了 318.00 美元的目标价格。汇丰银行在周三重申了 “买入” 评级，并设定了 425.00 美元的目标价格。Weiss Ratings 在 10 月 8 日（星期三）的研究报告中将安进的评级从 “持有（c+）” 上调至 “买入（b-）”。摩根士丹利在周五将安进的目标价格从 329.00 美元下调至 304.00 美元，并对该公司设定了 “同等权重” 评级。最后，Raymond James Financial 在 9 月 3 日（星期三）的研究报告中开始覆盖安进。他们对该股票设定了 “市场表现” 评级。一位分析师对该股票给予了强烈买入评级，十位分析师给予了买入评级，十位分析师给予了持有评级，一位分析师给予了卖出评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “适度买入”，共识目标价格为 332.85 美元。</p>
</div><p><strong>Check Out Our Latest Research Report on Amgen</strong></p>
<div class="lb-trans"><p><strong>查看我们关于安进的最新研究报告</strong></p>
</div><h2>Amgen Company Profile</h2>
<div class="lb-trans"><h2>安进公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.</p>
<div class="lb-trans"><p>安进公司在全球范围内发现、开发、生产和交付人类治疗药物。公司的主要产品包括用于治疗斑块型银屑病、类风湿性关节炎和银屑病关节炎的恩利昔（Enbrel）；用于治疗成人斑块型银屑病、银屑病关节炎和与贝赫切特病相关的口腔溃疡的 Otezla；用于治疗绝经后女性骨质疏松症的 Prolia；用于预防骨骼相关事件的 XGEVA；可降低心肌梗死、中风和冠状动脉再血管化风险的 Repatha；用于治疗免疫性血小板减少症患者的 Nplate；用于治疗复发性或难治性多发性骨髓瘤患者的 KYPROLIS；用于治疗红细胞数量低于正常水平和贫血的 Aranesp；用于治疗绝经后男性和女性骨质疏松症的 EVENITY；用于治疗野生型 RAS 转移性结直肠癌患者的 Vectibix；用于治疗急性淋巴细胞白血病患者的 BLINCYTO；用于治疗甲状腺眼病的 TEPEZZA；以及用于治疗慢性难治性痛风的 KRYSTEXXA。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另请参见</h2>
</div><ul>
<li>Five stocks we like better than Amgen</li>
<li>How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?</li>
<li>Disney's $1 Billion Deal Brings Its Magic to OpenAI</li>
<li>Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?</li>
<li>Why Amazon Could Be a $300 Stock Within Weeks</li>
<li>3 Grocery Stocks That Are Proving They Are Still Essential</li>
<li>Adobe Gets Post-Earnings Lift: Long-Term Outlook Favors Upside</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过安进</li>
<li>零售投资者如何交易多伦多证券交易所（TSX）？</li>
<li>迪士尼的 10 亿美元交易将其魔力带入 OpenAI</li>
<li>这些液化天然气股票是否准备迎来反弹？</li>
<li>为什么亚马逊可能在几周内成为 300 美元的股票</li>
<li>3 只杂货股票证明它们仍然是必需品</li>
<li>Adobe 在财报后获得提振：长期前景看涨</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding AMGN?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).</p>
<div class="lb-trans"><p><strong>想知道其他对 AMGN 持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取安进公司（NASDAQ:AMGN - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=AMGN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Amgen Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在安进吗？</h2>
</div><p>Before you consider Amgen, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑安进之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而安进并不在名单上。</p>
</div><p>While Amgen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然安进目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Coppell Advisory Solutions LLC 持有安进公司价值 136 万美元的股份